Treatment of Yeast Infection Affecting the Labia and Clitoris

Diagnosis Confirmation

The American College of Obstetricians and Gynecologists recommends confirming the diagnosis through wet-mount preparation with saline and 10% potassium hydroxide to demonstrate yeast or hyphae, and vaginal cultures for those with negative microscopy findings 1
A normal vaginal pH (4.0-4.5) should be checked before initiating treatment 3

The Centers for Disease Control and Prevention recommends topical antifungal options, including clotrimazole 1% cream applied to affected areas for 7-14 days, miconazole 2% cream applied to affected areas for 7 days, and butoconazole 2% cream for 3 days 1, 4, 5
The Infectious Diseases Society of America recommends oral therapy with fluconazole 150 mg as a single oral dose for mild-to-moderate infection, and fluconazole 150 mg every 72 hours for a total of 2-3 doses for severe infection 2

For mild to moderate external yeast infection, the American College of Obstetricians and Gynecologists recommends applying topical antifungal cream to the affected areas for 7-14 days 1, 5
For severe external yeast infection, the Centers for Disease Control and Prevention recommends longer duration of therapy (7-14 days) with topical agents, or fluconazole 150 mg orally every 72 hours for a total of 2-3 doses 1, 2, 4

For recurrent vulvovaginal candidiasis, the Infectious Diseases Society of America recommends initial induction therapy with topical agent or oral fluconazole for 10-14 days, followed by maintenance therapy with fluconazole 150 mg weekly for 6 months 1, 2
For non-albicans Candida species, the Centers for Disease Control and Prevention recommends options including boric acid 600 mg in gelatin capsule vaginally daily for 14 days, nystatin intravaginal suppositories 100,000 units daily for 14 days, and topical 17% flucytosine cream alone or with 3% AmB cream for 14 days 1, 2, 4

Both topical and oral antifungal formulations achieve >90% response rates for uncomplicated infections, according to the Infectious Diseases Society of America 1, 3
Treatment should not differ based on HIV status, with identical response rates expected, as recommended by the Centers for Disease Control and Prevention 1, 3